Sugi Predict

Sugi Predict / Compounds / SCHEMBL1034564

SCHEMBL1034564

SCHEMBL1034564

CCOC(=O)c1cc2ccccc2nc1C

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.68
▸ KDM4E B2RXH2 3/20 0.66
▸ ALDH1A1 P00352 3/20 0.66
▸ HPGD P15428 2/20 0.66
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ HSP90AA1 P07900 1/20 0.63
▸ MAPT P10636 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ HTT P42858 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5861172 0.86 TSHR (0.54) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL8582386 0.86 TSHR (0.55) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL20799519 0.85 KMT2A (0.65) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL30923332 0.85 ALDH1A1 (0.54) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL5193947 0.85 IKBKB (0.60) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL27411486 0.85 TSHR (0.57) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL2203793 0.85 ALDH1A1 (0.54) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL11058869 0.84 CYP3A4 (0.56) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL30201832 0.84 SMN1; SMN2 (0.60) TSHRKDM4EALDH1A1HPGDMEN1
SCHEMBL6601700 0.84 ALDH1A1 (0.54) TSHRKDM4EALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4459409-A METHYL-QUINOLINECARBOXYLIC ACID, OXIDATION, NICKEL PEROXIDE AMERICAN CYANAMID COMPANY (US) 1984-07-10 — — US claimed
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-02 — — US disclosed
WO-2023212565-A2 MOLECULAR EDITING OF MULTIPLE C-H BONDS BY LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY THE SCRIPPS RESEARCH INSTITUTE (US) 2023-11-02 — — WO disclosed
CN-113651820-A Urea compounds for dual IDO and TDO inhibitors 正大天晴药业集团股份有限公司 2021-11-16 — — CN disclosed
CN-110382500-B Urea compounds for dual IDO and TDO inhibitors 正大天晴药业集团股份有限公司 2021-08-10 — — CN disclosed
CN-111454264-B Luotonin A series compound and preparation method and application thereof 湖北中医药大学 2021-04-16 — — CN disclosed
CN-111454264-A L uotonin A series compound and preparation method and application thereof 湖北中医药大学 2020-07-28 — — CN disclosed
US-20140248635-A1 ALPHA-TUBULIN ACETYLTRANSFERASE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2014-09-04 — — US disclosed
CN-102584698-B 2-substutied-3-quinolinic acid ethyl ester compound, preparation method and applications thereof UNIV SOUTH CHINA NORMAL 2013-10-09 — — CN disclosed
CN-103153096-A Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers SENOMYX INC 2013-06-12 — — CN disclosed
US-20090253203-A1 Reprogramming a Cell by Inducing a Pluripotent Gene Through Use of a Small Molecule Modulator NUPOTENTIAL, INC. (US) 2009-10-08 — — US disclosed
US-20090099195-A1 Therapeutic Compounds 570 ASTRAZENECA AB (SE) 2009-04-16 — — US disclosed
WO-2008136756-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2008-11-13 — — WO disclosed
EP-0388620-B1 Process for the preparation of o-carboxypyridyl- and o-carboxyquinolylimidazolinones AMERICAN CYANAMID CO (US) 1994-11-02 — — EP disclosed
EP-0388620-A1 Process for the preparation of o-carboxypyridyl- and o-carboxyquinolylimidazolinones AMERICAN CYANAMID COMPANY (US) 1990-09-26 — — EP disclosed
US-4925944-A CONDENSATION AND CYCLIZATION IN AROMATIC SOLVENT AND SULFUR; ONE STEP; HERBICIDES AMERICAN CYANAMID COMPANY (US) 1990-05-15 — — US disclosed
US-4910327-A Reacting a corresponding aromatic primary amine with a ketoester AMERICAN CYANAMID COMPANY (US) 1990-03-20 — — US disclosed
US-4843162-A INTERMEDIATES FOR HERBICIDES AMERICAN CYANAMID COMPANY (US) 1989-06-27 — — US disclosed
US-4656283-A HERBICIDAL INTERMEDIATES AMERICAN CYANAMID COMPANY (US) 1987-04-07 — — US disclosed
US-4459408-A Process for the preparation of 2-(5-isopropyl-5-methyl-4-oxo-2-imidazolin-2-yl)-3-quinoline-carboxylic acid and alkyl 2-trichloromethyl-3-quinoline-carboxylate intermediates therefor AMERICAN CYANAMID COMPANY (US) 1984-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099195-A1 Therapeutic Compounds 570 OPRL1, OPRK1, OPRM1 TSHR 1066/4885KDM4E 2693/4885ALDH1A1 245/4885
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES TNNC1, PYGM, GYS1 TSHR 4703/4885KDM4E 3268/4885ALDH1A1 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.